4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile monohydrate is a chemical compound with a complex quinoline-based structure. It is a monohydrate salt form, featuring key functional groups including a quinoline core, a dichloro-methoxyphenylamino substituent, a methoxy group, a cyanide group, and a propoxy linker terminating in a 4-methylpiperazine moiety. This compound is a key intermediate in the synthesis of Bosutinib (SKI-606). Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor approved for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy. The specific structural modifications, particularly the 4-methylpiperazinepropoxy side chain, are critical for its kinase inhibitory activity and pharmacokinetic properties. As a high-value synthetic intermediate, its production and quality control are crucial steps in the manufacturing process of the active pharmaceutical ingredient (API) Bosutinib. Handling requires appropriate safety precautions due to its potential toxicity as a pharmaceutical intermediate.